Where does Translational Drug Development, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Translational Drug Development, LLC ranks #20,550 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Translational Drug Development, LLC hold?

Translational Drug Development, LLC holds 14 US utility patents granted between 2018 and 2024, spanning 4 technology areas.

What is Translational Drug Development, LLC's Innovation Score?

Translational Drug Development, LLC has an Innovation Score of 30.8 out of 100 (36th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Translational Drug Development, LLC focus on?

Translational Drug Development, LLC's top technology area is C07D (Heterocyclic Compounds) with 14 patents, ranking #603 of 3,165 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Translational Drug Development, LLC's patent grant rate increasing or decreasing?

Translational Drug Development, LLC's recent grant velocity is +500% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Translational Drug Development, LLC's patents?

Translational Drug Development, LLC's patents average 17.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Translational Drug Development, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Translational Drug Development, LLC

USPTO PatentsView assignee record - 14 granted patents across 4 technology areas, recorded in grant years 2018–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Translational ranks #20,550 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 4 technology areas.

#20,550
of 49,997 US assignees by volume: 36th percentile
by Innovation Score (30.8/100): 17.1
avg claims per patent: +500%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R20550 · US Corporation #20,550 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #20,550/49,997
PHOTO-FINISH Thompson Brothers &
CPC-NARROW C07D · 4 areas
INNOV-THIN 30.8/100
CLAIMS-RICH 17.1 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +500% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Thompson Brothers & Company LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Translational’s 30.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (30%) Velocity 4.2 pts (14%) Breadth 7.1 pts (23%) Claim depth 10.2 pts (33%)

Qualcomm Incorporated · highest

85
Translational Drug… · this assignee

31
3D Lighting… · lowest

7

What this shows Translational's Innovation Score is 30.8/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Translational?

Each dot is one of Translational’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Translational’s own 17.1 claims/patent is at or below the 18.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Translational vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Translational's grants concentrate

Translational Drug Development, LLC is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2020 (6 grants) versus a trough of 1 in 2018. By volume, Translational sits between Thompson Brothers & Company LLC and Tritana Intellectual Property Ltd..

Translational's three-year grant acceleration

Translational Drug Development, LLC shows 5 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Thompson Brothers…

14
Tianma Advanced D…

14
Tie Down

14
Touchstream

14
Tria Network Syst…

14
Tribogenics

14
Trice Medical

14
Tritana Intellect…

14
Translational Dru… ◀

14

What this shows Translational holds 14 patents at rank #20,552, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Translational

By rank, the assignees closest to #20,552 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Translational's primary technology class.

Translational's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Translational Drug Development, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	7.1%
2019	1	7.1%
2020	6	42.9%
2021	1	7.1%
2022	2	14.3%
2023	2	14.3%
2024	1	7.1%

Which technologies does Translational Drug Development, LLC patent most?

C07D - Heterocyclic Compounds 14

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

C07K - Peptides 3

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Translational Drug Development, LLC's patent record in context - here's where to go next.

Translational Drug Development, LLC's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #20,550 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Translational Drug Development, LLC against Thompson Brothers & Company LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.